ABLA
JAZZ icon

Alan B. Lancz & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Alan B. Lancz & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Buy
+1,075
New +$188K 0.2% 128

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Alan B. Lancz & Associates's JAZZ Position: Q1 2026 in Review

Alan B. Lancz & Associates opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 1,075 shares worth $203K. The stake represents 0.2% of the portfolio and ranks #128 among its holdings.

570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Alan B. Lancz & Associates held 1,075 shares of Jazz Pharmaceuticals worth $203K as of Q1 2026.
  • Jazz Pharmaceuticals was a new Alan B. Lancz & Associates position in Q1 2026.
  • Jazz Pharmaceuticals made up 0.2% of Alan B. Lancz & Associates's portfolio in Q1 2026, its #128 holding.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Alan B. Lancz & Associates's 13F filing for Q1 2026, filed 5 May 2026.